Oncotarget

Research Papers:

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration

Massimo Nabissi _, Maria Beatrice Morelli, Massimo Offidani, Consuelo Amantini, Silvia Gentili, Alessandra Soriani, Claudio Cardinali, Pietro Leoni and Giorgio Santoni

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:77543-77557. https://doi.org/10.18632/oncotarget.12721

Metrics: PDF 1936 views  |   HTML 3158 views  |   ?  


Abstract

Massimo Nabissi1,*, Maria Beatrice Morelli2,*, Massimo Offidani3, Consuelo Amantini4, Silvia Gentili3, Alessandra Soriani2, Claudio Cardinali2, Pietro Leoni3, Giorgio Santoni1

1School of Pharmacy, Experimental Medicine Section, University of Camerino, Camerino, Italy

2Department of Molecular Medicine, Sapienza University, Rome, Italy

3Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy

4School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy

*These authors have contributed equally to this work

Correspondence to:

Massimo Nabissi, email: massimo.nabissi@unicam.it

Keywords: carfilzomib, THC, CBD, multiple myeloma, immuno-proteasome, combination therapy

Received: September 01, 2016     Accepted: October 05, 2016     Published: October 18, 2016

ABSTRACT

Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor bortezomib, to induce cell death. In other type of human cancers, the combination of CBD with Δ9-tetrahydrocannabinol (THC) was found to act synergistically with other chemotherapeutic drugs suggesting their use in combination therapy. In the current study, we evaluated the effects of THC alone and in combination with CBD in MM cell lines. We found that CBD and THC, mainly in combination, were able to reduce cell viability by inducing autophagic-dependent necrosis. Moreover, we showed that the CBD-THC combination was able to reduce MM cells migration by down-regulating expression of the chemokine receptor CXCR4 and of the CD147 plasma membrane glycoprotein. Furthermore, since the immuno-proteasome is considered a new target in MM and also since carfilzomib (CFZ) is a new promising immuno-proteasome inhibitor that creates irreversible adducts with the β5i subunit of immuno-proteasome, we evaluated the effect of CBD and THC in regulating the expression of the β5i subunit and their effect in combination with CFZ. Herein, we also found that the CBD and THC combination is able to reduce expression of the β5i subunit as well as to act in synergy with CFZ to increase MM cell death and inhibits cell migration. In summary, these results proved that this combination exerts strong anti-myeloma activities.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12721